Changes in Hong Kong stocks | Conoa-B (02162) rose more than 6% in the afternoon, Kang Yueda was approved for listing on adolescent atopic dermatitis indications

The Zhitong Finance App learned that Conoa-B (02162) rose more than 6% in the afternoon. As of press release, it had risen 4.45% to HK$85.4, with a turnover of HK$187 million.

^{According to news, recently, according to Connoah's official WeChat account, the company announced that the self-developed core product Kangyueda® (supricimab) has been approved for marketing by the State Drug Administration for moderate to severe atopic dermatitis. A fourth approved indication was added to the product, and its dermatological indications have further expanded from adults to young patients aged 12 and above.}

^{Chen Bo, Chairman and CEO of Connoya, said that the approval of Kangyueda® for adolescent atopic dermatitis is another important milestone achieved by Kangyueda ® in the field of dermatology after moderate to severe atopic dermatitis in adults. It has filled the gap in domestic biologics treatment for moderate and severe atopic dermatitis among young people in China, and brought new targeted biologic treatment options for young and severe atopic dermatitis patients in China.}